Company Overview - Kefu Medical Technology Co., Ltd. is a leading large-scale, comprehensive home medical device enterprise in China, engaged in the research, production, sales, and service of medical devices [2] - The company's main products include blood glucose systems, uric acid systems, blood pressure monitors, blood oxygen meters, infrared thermometers, and various other medical and healthcare products [2] - Kefu Medical has received honors such as "Changsha Intelligent Manufacturing Pilot Enterprise" and "Hunan High-tech Enterprise," with its self-developed products like hearing aids and nebulizers being at the leading level domestically [2] Financial Performance - For the third quarter of 2024, Kefu Medical reported a revenue of 2.249 billion yuan, representing a year-on-year increase of 5.87%, and a net profit of 252 million yuan, up 4.12% year-on-year, with a gross profit margin of 51.38% [2] - As of April 15, the company's stock closed at 33.12 yuan, with a rolling price-to-earnings (PE) ratio of 26.21 times and a total market capitalization of 6.925 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 46.44 times, with a median of 30.39 times, placing Kefu Medical at the 64th position in the industry ranking [1][3] - The company has a price-to-book (PB) ratio of 1.46, compared to the industry average of 4.75 [3]

午后高位股持续下挫 连云港等多股跌停 智通财经4月15日电，午后连云港、海鸥住工、远大控股、瑞茂通跌停，回盛生物跌超10%，中源家 居、天顺股份、秋乐种业、飞力达、哈三联、凯美特气等跌幅靠前。 ...

Core Viewpoint - The A-share and Hong Kong stock markets experienced significant declines, with major indices dropping over 2% to 3% amid ongoing market volatility and external pressures [2][3][5]. Market Performance - As of the report, the Shanghai Composite Index fell by 2.22% to 3075.75, while the Shenzhen Component Index dropped by 3.04% to 9138.12. The ChiNext Index also saw a decline of over 3% [2][3]. - In the Hong Kong market, the Hang Seng Index opened down by 3.81%, and the Hang Seng Tech Index fell by over 5%. Notably, the pharmaceutical and consumer sectors faced significant losses, with companies like Wan Zhou International and WuXi Biologics experiencing declines of nearly 10% and over 8%, respectively [5]. Corporate Actions - Multiple companies announced share buyback and stake increase plans, with at least 56 A-share listed companies releasing such announcements between April 7 and 8. This included nearly 140 companies disclosing share repurchase plans [15]. - China Aluminum Group and China Minmetals Group both announced plans to increase their stakes in listed companies, with China Aluminum planning to invest between 1 billion to 2 billion RMB [14]. Government and Institutional Support - The "national team" has been actively buying ETFs to stabilize the market, with significant purchases reported from Central Huijin Investment and other state-owned entities [17][21]. - The People's Bank of China indicated readiness to provide sufficient re-lending support to Central Huijin, further emphasizing the commitment to market stability [17]. Investment Outlook - Analysts maintain a relatively optimistic outlook for the A-share market, suggesting that despite uncertainties from trade tensions, the influx of capital and institutional support could lead to a more stable market environment [23]. - The focus on high-quality and high-dividend assets is expected to prevail, with potential opportunities arising from recent market dips [23].

4月8日，可孚医疗今日收盘32.29元，上涨5.94%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到25.55倍，总市值67.52亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均44.58倍，行业中值28.55倍，可孚医疗排 名第64位。 资金流向方面，4月8日，可孚医疗主力资金净流出547.73万元，近5日总体呈流出状态，5日共流出 312.30万元。 可孚医疗科技股份有限公司是一家国内领先的大型、综合性家用医疗器械企业，专业从事医疗器械的研 发、生产、销售和服务。公司的主要产品包括血糖系统、尿酸系统、血压计、血氧仪、红外线体温计、 胃幽门螺杆菌快速检测试纸、早孕检测试纸、胎心仪、听诊器、电子体重秤、轮椅、代步车、护理床、 移位机、听力计、助听器、助行器、腋下拐、手杖、敷贴/敷料类、造口袋、口罩、手套、医用防护 服、纱布/绷带类、棉球/棉签/棉片类、消毒产品、口腔护理、呼吸机、制氧机、氧立得手提便携式制氧 器、氧气袋、雾化器、鼻腔护理、理疗仪、按摩器、艾叶及制成品、温灸产品、拔罐器、刮痧板。公司 在技术工艺方面先后获得了"长沙市智能制造试点企业"、"湖南省高新技术企业"、"长沙 ...

Core Viewpoint - The A-share market showed a strong performance on April 8, with major indices closing in the green, indicating a positive market sentiment driven by significant policy support from government entities [1][2]. Market Performance - The Shanghai Composite Index closed at 3145.55 points, up 1.58% - The Shenzhen Component Index closed at 9424.68 points, up 0.64% - The ChiNext Index closed at 1840.31 points, up 1.83% - Total trading volume in the Shanghai and Shenzhen markets exceeded 1.6 trillion yuan, with over 3200 stocks recording gains [1][2]. Sector Performance - Agricultural stocks surged, with companies like Qiule Seed Industry and Hualu Biology hitting the daily limit - Retail stocks continued their upward trend, with Kid King and Guofang Group also reaching the daily limit - State-owned enterprises and technology innovation stocks were active, with companies like COFCO Technology and Sinotrans both hitting the daily limit - The fruit supply chain sector experienced a collective adjustment, with companies like Luxshare Precision and Dongshan Precision hitting the daily limit - The automotive industry chain saw a decline, with companies like Jinbei Automobile and Asia-Pacific Shares collectively hitting the daily limit [4][5]. Policy Support - On April 8, the Central Huijin, the People's Bank of China, and the National Financial Regulatory Administration collectively announced measures to support the capital market, emphasizing their role as a "national team" [7][10]. - The National Financial Regulatory Administration optimized policies for insurance funds entering the market, increasing the allocation ratio for equity assets, which could potentially bring in an additional 1.66 trillion yuan in market funds [8][10]. - State-owned asset management platforms like China Chengtong and China Guoxin announced significant purchases of central enterprise and technology innovation stocks, creating a strong market support coalition [9][10]. Market Outlook - Analysts believe that the recent policy actions are crucial for maintaining market liquidity and fostering a positive feedback loop for microeconomic entities [10][11]. - The overall valuation of A-shares is considered attractive, with a focus on core assets, as the market is expected to stabilize despite short-term fluctuations [11][15]. - The government is likely to implement further fiscal policies aimed at expanding domestic demand and promoting consumption, with potential measures including accelerated issuance of special bonds and increased subsidies [25][26].

湖南启元律师事务所 关于 可孚医疗科技股份有限公司 2025年第一次临时股东大会的 法律意见书 二零二五年四月 1 致：可孚医疗科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受可孚医疗科技股份有限公司 （以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第一次临时股东 大会（以下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席 会议人员及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证， 并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》（以 下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《可孚医 疗科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具本法 律意见书。 本所律师声明如下： 1、刊登在深圳证券交易所网站（https://www.szse.cn/）的与本次股东大会有 关的通知等公告事项； 2、出席会议的股东或其代理人的身份证明文件、授权委托书等； 3、本次股东大会股权登记日的公司股东名册、出席现场会议的股东的到会登 记 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-014 可孚医疗科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会未出现否决议案的情形。 （1）现场会议召开时间：2025年4月3日（星期四）15:00； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年4月3日的交易时间，即9:15 - 9:25，9:30 - 11:30和13:00 - 15:00；通过深圳 证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间为：2025 年4月3日9:15 - 15:00。 2. 现场会议召开地点：长沙市雨花区万家丽中路一段426号高桥大健康医药 城8楼801会议室。 3. 会议召开方式：采取现场投票与网络投票相结合的方式。 4. 会议召集人：公司董事会。 2. 本次股东大会未涉及变更以往股东大会已通过的决议。 5. 会议主持人：董事长张敏先生。 6. 会议出席情况： 出席本次会议的股东及股东代表共149 ...

3月28日，可孚医疗今日收盘35.04元，下跌1.02%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到27.73倍，总市值73.27亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.22倍，行业中值32.57倍，可孚医疗排 名第63位。 最新一期业绩显示，2024年三季报，公司实现营业收入22.49亿元，同比5.87%；净利润2.52亿元，同比 4.12%，销售毛利率51.38%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)63可孚医疗27.7328.811.5473.27亿行业平均 45.2249.254.85107.95亿行业中值32.5731.042.4948.28亿1硕世生物-1928.41-1928.411.2139.84亿2诺唯 赞-570.10-570.102.4696.93亿3博晖创新-299.11-184.163.3045.91亿4康泰医学-292.1334.272.9856.81亿5华 大基因-217.12237.502.25220.63亿6奥精医疗-119.63-119.631.5221.67亿7睿昂基因-82.87-82.871.2911. ...

Group 1: Company Strategy and Product Focus - The company positions itself as a leading enterprise in personal health management with a rich product line, focusing on core product development while exploring emerging product areas, including AI applications in health management [2] - In 2023, the company implemented a product focus strategy to enhance the competitiveness and brand influence of its core products, aiming for steady growth in sales scale and market share [2] Group 2: Product Structure and Market Dynamics - The diverse product structure provides strong risk resistance, allowing the company to maintain competitive capabilities despite fluctuations in product sales, such as the rise and fall of products like thermometers and masks [2] - The company has made strategic adjustments in 2024 to focus on core product development across supply chain, R&D, production, and distribution [2] Group 3: Financial Performance and Profitability - The company's gross margin has steadily increased due to product structure optimization, product upgrades, and expanded self-production capabilities [4] - The establishment of production bases has enabled the company to achieve self-research and production of core products, enhancing product performance and reducing production costs [4] Group 4: Hearing Aid Market Potential - The hearing aid market in China has significant growth potential, with a current penetration rate of less than 5%, compared to over 30% in developed countries [5] - The elderly population with hearing loss in China has reached 120 million, with a high incidence of moderate to severe hearing loss among those aged 65 and above [5] - The government has initiated actions to promote early screening and intervention for hearing loss, creating favorable conditions for industry growth [5] Group 5: M&A Plans - The company is actively looking for merger and acquisition opportunities within the industry that align with its strategic direction and can enhance its competitive advantage in niche markets [6]

注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未超过本激励 计划公告时公司股本总额的 1%。公司全部在有效期内的股权激励计划所涉及的标的股票总数累计不超过本 激励计划公告时公司股本总额的 20%。 2、上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入所致。 可孚医疗科技股份有限公司董事会 可孚医疗科技股份有限公司 2024 年限制性股票激励计划预留授予激励对象名单 （预留授予日） 第二类限制性股票预留授予分配情况及数量 | 职务 | 获授限制性股票 | 占本激励计划授出限 | 占目前公司股本 | | --- | --- | --- | --- | | | 数量（股） | 制性股票总数的比例 | 总额的比例 | | 其他核心人员、管理人员、技术 | 300,000 | 4.52% | 0.14% | | 人员、骨干人员（38 人） | | | | | 合计 | 300,000 | 4.52% | 0.14% | 2025 年 3 月 19 日 ...